Prothena | PRTA - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Akebia Therapeutics USD 63.08M 8.26M 2025-12
ALKERMES USD 1.75B 1.43B 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amgen USD 4.78B 1.12B 2026-03
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Exelixis USD 359.47M 3.28M 2026-03
Immunic USD 23.33M 2.67M 2025-12
Incyte USD 5.62B 4.5B 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
MacroGenics USD 21.2M 32.13M 2026-03
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
Prothena USD 25.29M 1.94M 2026-03
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03